4.7 Review

Characteristics of the (Auto)Reactive T Cells in Rheumatoid Arthritis According to the Immune Epitope Database

期刊

出版社

MDPI
DOI: 10.3390/ijms24054296

关键词

rheumatoid arthritis; memory T cells; shared epitope; neoepitopes; peptides

向作者/读者索取更多资源

T cells play a crucial role in the development of rheumatoid arthritis (RA). A comprehensive review based on the analysis of the Immune Epitope Database (IEDB) was conducted to better understand the contribution of T cells to RA. It was found that an immune CD8+ T cell senescence response is present in RA and inflammatory diseases, driven by viral antigens and self-apoptotic peptides. Additionally, pro-inflammatory CD4+ T cells in RA are selected by MHC class II and immunodominant peptides derived from molecular chaperones, host peptides, and bacterial cross-reactive peptides.
T cells are known to be involved in the pathogenesis of rheumatoid arthritis (RA). Accordingly, and to better understand T cells' contribution to RA, a comprehensive review based on an analysis of the Immune Epitope Database (IEDB) was conducted. An immune CD8+ T cell senescence response is reported in RA and inflammatory diseases, which is driven by active viral antigens from latent viruses and cryptic self-apoptotic peptides. RA-associated pro-inflammatory CD4+ T cells are selected by MHC class II and immunodominant peptides, which are derived from molecular chaperones, host extra-cellular and cellular peptides that could be post-translationally modified (PTM), and bacterial cross-reactive peptides. A large panel of techniques have been used to characterize (auto)reactive T cells and RA-associated peptides with regards to their interaction with the MHC and TCR, capacity to enter the docking site of the shared epitope (DRB1-SE), capacity to induce T cell proliferation, capacity to select T cell subsets (Th1/Th17, Treg), and clinical contribution. Among docking DRB1-SE peptides, those with PTM expand autoreactive and high-affinity CD4+ memory T cells in RA patients with an active disease. Considering original therapeutic options in RA, mutated, or altered peptide ligands (APL) have been developed and are tested in clinical trials.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据